{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:40:34Z","timestamp":1790797234173,"version":"4.1.0"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP20K16095"],"award-info":[{"award-number":["JP20K16095"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Invasive fungal disease (IFD) is an important cause of morbidity and mortality in patients with hematological malignancies. As chronic lymphocytic leukemia (CLL) is a rare hematological malignancy in Japan, IFD incidence in Japanese patients with CLL is unclear. This study aimed to investigate IFD incidence in Japanese patients with CLL. This retrospective cohort study used data of patients with CLL registered between April 2008 and December 2019 in the Medical Data Vision database (n = 3484). IFD incidence after CLL diagnosis in the watch-and-wait (WW) and drug therapy (DT) groups was 1.5% and 9.2%, respectively. The most common type of IFD was invasive aspergillosis (28.1%). Cox proportional hazards multivariate analysis revealed that DT (hazard ratio [HR]: 2.13) and steroid use (HR: 4.19) were significantly associated with IFD occurrence. IFD incidence was significantly higher in the DT group than in the WW group (log-rank p &lt; 0.001); however, there was no significant between-group difference in the time to IFD onset or the type of IFD (p = 0.09). This study determined the incidence of IFD in patients with CLL during WW. Physicians should monitor for IFD, even among patients with CLL undergoing the WW protocol.<\/jats:p>","DOI":"10.3390\/curroncol29050264","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:21:25Z","timestamp":1651652485000},"page":"3242-3251","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Invasive Fungal Disease in Patients with Chronic Lymphocytic Leukemia in Japan: A Retrospective Database Study"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0587-0091","authenticated-orcid":false,"given":"Takeo","family":"Yasu","sequence":"first","affiliation":[{"name":"Pharmaceutical Education and Research Center, Department of Medicinal Therapy Research, Meiji Pharmaceutical University, Noshio, Kiyose 204-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotono","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Pharmaceutical Education and Research Center, Department of Medicinal Therapy Research, Meiji Pharmaceutical University, Noshio, Kiyose 204-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4112-6035","authenticated-orcid":false,"given":"Manabu","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Noshio, Kiyose 204-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"490.e1","DOI":"10.1016\/j.cmi.2014.12.021","article-title":"Invasive infections due to filamentous fungi other than Aspergillus: Epidemiology and determinants of mortality","volume":"21","author":"Slavin","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Valentine, J.C., Morrissey, C.O., Tacey, M.A., Liew, D., Patil, S., Peleg, A.Y., and Ananda-Rajah, M.R. (2019). A population-based analysis of invasive fungal disease in haematology- oncology patients using data linkage of state-wide registries and administrative databases: 2005\u20132016. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3901-y"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3314\/jjmm.52.117","article-title":"Epidemiology of visceral mycoses in autopsy cases in Japan: Comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in Annual of Pathological Autopsy Cases in Japan","volume":"52","author":"Kume","year":"2011","journal-title":"Med. Mycol. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s12185-012-1210-y","article-title":"Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies","volume":"96","author":"Kurosawa","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"594.e7","DOI":"10.1016\/j.cmi.2015.02.019","article-title":"Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: A prospective observational study","volume":"21","author":"Hsu","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1002\/cam4.1805","article-title":"Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification","volume":"7","author":"Muto","year":"2018","journal-title":"Cancer Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jiac.2021.08.005","article-title":"Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib","volume":"27","author":"Holowka","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15033","DOI":"10.1038\/s41598-020-72135-y","article-title":"Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan","volume":"14","author":"Takazono","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: A persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"756237","DOI":"10.3389\/fmed.2021.756237","article-title":"Clinical characteristics and prognostic risk factors of patients with proven invasive pulmonary aspergillosis: A single-institution retrospective study","volume":"8","author":"Tong","year":"2021","journal-title":"Front. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s41669-017-0024-5","article-title":"Cost of illness of Japanese patients with chronic lymphocytic leukemia (CLL) and budget impact of the market introduction of ibrutinib","volume":"1","author":"Mahlich","year":"2017","journal-title":"Pharmacoecon Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"ofw268","DOI":"10.1093\/ofid\/ofw268","article-title":"Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000\u20132013","volume":"4","author":"Vallabhaneni","year":"2017","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/ciy181","article-title":"Epidemiology and outcomes of hospitalizations with invasive aspergillosis in the United States, 2009\u20132013","volume":"67","author":"Zilberberg","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","article-title":"First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial","volume":"17","author":"Eichhorst","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-008-0566-9","article-title":"Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"88","author":"Elter","year":"2009","journal-title":"Ann. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.leu.2403258","article-title":"Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia","volume":"18","author":"Lundin","year":"2004","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","article-title":"Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors","volume":"4","author":"Ryan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1002\/cam4.4293","article-title":"Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study","volume":"10","author":"Carpio","year":"2021","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/ejh.13020","article-title":"Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies","volume":"100","author":"Tillman","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: Phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Eichhorst","year":"2015","journal-title":"Ann. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/264\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:05:54Z","timestamp":1760137554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["curroncol29050264"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29050264","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]}}}